ADMA Biologics is Thursday's IBD Stock Of The Day. After an accounting debacle hammered shares in 2024, ADMA stock is making ...

A discrete choice experiment (DCE) revealed no meaningful difference in preference between dual biologic therapy (DBT) or monotherapy among patients with inflammatory bowel disease (IBD ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The following is a summary of "Treatment Sequencing in Inflammatory Bowel Disease: Towards Clinical Precision Medicine," published in the March 2025 issue of Best Practice & Research Clinical ...

Background: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ...

This study highlights the link between plant-based diets and reduced IBD risk, suggesting dietary choices play a crucial role ...

Direct costs of IBD care vary by region, with biologic therapies now dominating expenses, particularly in the US due to high drug prices. Socioeconomic and racial disparities exacerbate access ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

The average annual expense per IBD patient grew from about $8,500 in 2009 to nearly $15,800 by 2019 in the U.S. This rise is largely attributed to the escalating costs of biologic therapies ...

Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and ...

Inflammatory bowel disease (IBD) is impacted by genetic, environmental and immunological factors, where the imbalance in T-cell immune responses significantly promotes its progression. In recent years ...